ImmuCell Corporation (Nasdaq: ICCC) has developed the First Defense® product line to deliver Immediate Immunity™ against E. coli, coronavirus, and rotavirus infections, the primary pathogens that cause scours (uncontrolled diarrhea), which is the leading disease risk to newborn dairy and beef calves. The Company estimates the cost of scours in the US to be over $700 million per year. The use of First Defense® immediately after birth enables producers to realize the genetic potential of their newborn livestock assets.

The Company is also in the final stages of achieving FDA approval for Re-Tain™, a bacteriocin-based product to treat subclinical mastitis in lactating cows without the use of traditional human antibiotics. Mastitis infections result in approximately $2 BILLION in economic losses to the U.S. dairy industry annually. Reducing the use of antibiotics in the human food chain is a national imperative.

Annual Meeting of Stockholders


Wednesday, June 10, 2020 at 3:00PM ET

2019 Annual Report Form 10-K

Proxy Statement

Recent Events

Lytham Partners Virtual Investor Conference

Wednesday, May 20, 2020

Manufacturing Expansion

To meet the growing demand of its First Defense® product line, ImmuCell began construction of an expanded manufacturing facility to increase production capacity.

Conference Calls

05-14-20 – First Quarter Fiscal Year 2020 Conference Call

Replay   |   Transcript

02-19-20 – Fourth Quarter Fiscal Year 2019 Conference Call

Replay   |   Transcript

11-11-19 – Third Quarter Fiscal Year 2019 Conference Call

Replay   |   Transcript

08-13-19 – Second Quarter Fiscal Year 2019 Conference Call

Replay   |   Transcript

05-14-19 – First Quarter Fiscal Year 2019 Conference Call

Replay   |    Transcript

02-14-19 – Fourth Quarter & Fiscal Year 2018 Conference Call

Replay   |    Transcript